Diabetes Clinical Trials in Newport News
View 33 new treatments for Diabetes in Newport News, VA, and nearby areas, such as Hampton. Every day, Power helps hundreds of diabetes patients connect with leading medical research.Filter Results
Condition
All
How old are you?
Trial Phase
All
Trial Status
All
Metformin vs Insulin for Gestational Diabetes
Research Clinic, Norfolk + 1 more
This is a non-inferiority patient-centered and pragmatic comparative-effectiveness pregnancy randomized controlled trial (RCT) with postpartum maternal and child follow-up through 2 years of 1,572 individuals with gestational diabetes mellitus (GDM) randomized to oral metformin versus injectable insulin. This study will determine if metformin is not inferior to insulin in reducing adverse pregnancy outcomes, is comparably safe for exposed individuals and children, and if patient-reported factors, including facilitators of and barriers to use, differ between metformin and insulin. A total of 1,572 pregnant individuals with GDM who need pharmacotherapy will be recruited at 20 U.S. sites using consistent treatment criteria to metformin versus insulin. Participants and their children will be followed through delivery to two years postpartum.Show More
Recruiting
No Placebo Trial
Phase 4
Est. 3 - 6 Weeks
Kartik Venkatesh, MD, PhD
Principal Investigator
Faricimab for Diabetic Macular Edema
Genentech Clinic, Norfolk + 2 more
This study is designed to investigate treatment response in treatment-naïve underrepresented patients with diabetic macular edema (DME) who are treated with faricimab. The study population will consist of participants ≥18 years of age who self-identify as Black/African American, Hispanic/Latino American, or Native American/Alaska Native/Native Hawaiian or other Pacific Islander; in addition, a cohort of Asian Indian participants will be enrolled in India.Show More
Recruiting
No Placebo Trial
Phase 4
Est. 6 - 12 Weeks
Clinical Trials
Study Director
Naltrexone + Bupropion for Obesity
Currax Clinic, Norfolk + 3 more
This trial studies the effects of a medication combination (naltrexone and bupropion) on heart health. It targets patients to see if this treatment increases the risk of major heart problems. The study also includes advice on diet and exercise. Naltrexone and bupropion have been used in combination for weight loss, but they have been associated with various adverse effects, including neuropsychiatric disorders and cardiovascular risks.Show More
Recruiting
Phase 4
Est. 3 - 12 Weeks
Unregistered Study Lead
Research Team
Ranibizumab PDS Implant for Diabetic Retinopathy
Hoffmann-La Roche Clinic, Norfolk + 1 more
Study GR41675 is a Multicenter, Randomized Study in Participants with Diabetic Retinopathy (DR) Without Center-Involved Diabetic Macular Edema (CI-DME) to Evaluate the Efficacy, Safety of the Port Delivery System with Ranibizumab (PDS) Relative to the Comparator ArmShow More
Waitlist
No Placebo Trial
Phase 3
Est. 3 - 6 Weeks
Clinical Trials
Study Director
CagriSema for Type 2 Diabetes
Novo Nordisk Clinic, Newport News + 1 more
This study will look at how much CagriSema helps participants with type 2 diabetes lower their blood sugar and body weight. CagriSema is a new investigational medicine. Doctors may not yet prescribe CagriSema. CagriSema will be compared to a "dummy" medicine (also called "placebo") that has no effect on the body. Participants will get either CagriSema or "dummy" medicine. Which treatment participants get is decided by chance. For each participant, the study will last for about one year.Show More
Recruiting
Phase 3
Est. 6 - 12 Weeks
Clinical Transparency (dept. 2834)
Study Director
IcoSema for Type 2 Diabetes
Novo Nordisk Clinic, Norfolk + 1 more
This trial will test a new weekly injection called IcoSema, which combines two drugs, in people with type 2 diabetes. The goal is to see if it controls blood sugar better than just using one of the drugs alone. Participants will receive either IcoSema or the single drug and will be monitored for several months.Show More
Waitlist
No Placebo Trial
Phase 3
Est. 3 - 12 Weeks
Clinical Transparency (dept. 2834)
Study Director
Semaglutide + Low-Dose Insulin Glargine for Type 2 Diabetes
Novo Nordisk Clinic, Chesapeake + 1 more
This study compares semaglutide, together with a lower dose of insulin glargine, to a higher dose of insulin glargine in participants with type 2 diabetes. The study looks at how well the study medicines control blood glucose levels. Participants will either get semaglutide together with a lower dose of insulin glargine or a higher dose of insulin glargine. The study will last for about 47 weeks (approximately 11 months). Participants will have 9 clinic visits, 15 phone/video calls and 1 home visit. Participants will be asked to wear a sensor that measures their blood sugar all the time in 2 periods of 10 days during the study.Show More
Recruiting
No Placebo Trial
Phase 3
Est. 6 - 12 Weeks
Clinical Transparency (dept. 2834)
Study Director
Orforglipron for Type 2 Diabetes and Obesity
Eli Lilly Clinic, Suffolk + 2 more
This trial is testing a new diabetes medication called orforglipron to see if it is safer and more effective than insulin in people with type 2 diabetes who are overweight or obese and at higher risk for heart problems. The study will last several years and involve multiple visits.Show More
Recruiting
No Placebo Trial
Phase 3
Est. 5 - 8 Weeks
Call 1-877-CTLILLY (1-877-285-4559) or 1-317-615-4559 Mon - Fri 9 AM - 5 PM Eastern time (UTC/GMT - 5 hours, EST)
Study Director
ENERGI-F703 GEL for Diabetic Foot Ulcers
Energenesis Biomedical Clinic, Suffolk + 1 more
This trial is testing a special gel called ENERGI-F703 GEL to see if it can help heal foot ulcers in people with diabetes. The study focuses on patients with mild to moderate diabetic foot ulcers. The gel works by creating a good environment for skin repair and protecting the wound from germs. ENERGI-F703 gel, containing adenine as its active ingredient, has shown promise in accelerating wound healing in diabetic mice.Show More
Recruiting
Phase 3
Est. 5 - 8 Weeks
Unregistered Study Lead
Research Team
IcoSema for Type 2 Diabetes
Novo Nordisk Clinic, Newport News + 2 more
This trial will test a new weekly injection called IcoSema, which combines two drugs, in people with type 2 diabetes. The goal is to see if it controls blood sugar better than the existing drug, semaglutide. Participants will be randomly assigned to receive either IcoSema or semaglutide for several months.Show More
Waitlist
No Placebo Trial
Phase 3
Est. 6 - 12 Weeks
Clinical Transparency (dept. 1452)
Study Director
Page 1 of 3
Frequently Asked Questions
Explore related conditions